Objectives: This study sought to assess the value of bioresorbable vascular scaffolds (BVS) in patients with in-stent restenosis (ISR).
Background: Currently both drug-eluting stents (DES) and drug-eluting balloons (DEB) are recommended in patients with ISR. However, the value of BVS in this setting remains unclear.
Methods: RIBS VI (Restenosis Intra-stent: drug-eluting Balloon vs everolimus-eluting Stent) was a prospective multicenter study (19 Spanish sites) that included 141 patients treated with BVS for either bare-metal stent (BMS) ISR or DES-ISR. Late angiography was scheduled at 6 to 9 months. Inclusion/exclusion criteria were similar to those used in the RIBS IV (patients with DES-ISR) and RIBS V (patients with BMS-ISR) trials, where DEB (n = 249) was compared with everolimus (EES)-DES (n = 249). Results of BVS in RIBS VI were compared with those obtained with DEB and EES in the RIBS IV and V trials.
Results: On late angiography (n = 134; 95% of eligible) the in-segment minimal lumen diameter (primary endpoint) was 1.87 ± 0.5 mm, late lumen loss was 0.23 ± 0.4 mm, and restenosis rate was 11%. At 1-year follow-up (100% of patients) no patient died, 4 (2.8%) experienced a myocardial infarction, and 16 (11.3%) required target lesion revascularization. One patient (0.7%) who discontinued antiplatelet therapy experienced definitive BVS thrombosis. Freedom from cardiac death, myocardial infarction, and target lesion revascularization was 86%. The minimal lumen diameter at follow-up after BVS was similar to that obtained with DEB (1.88 ± 0.6 mm; p = NS) but smaller than that achieved after EES (2.16 ± 0.7 mm; p < 0.001). Likewise, target lesion revascularization rates after BVS were similar to those seen with DEB (10.4%) but higher than with EES (3.2%; p < 0.001). Results remained unchanged after adjusting for potential confounders in baseline characteristics.
Conclusions: This study suggests the safety and efficacy of BVS in patients with ISR. In this challenging anatomic scenario BVS obtained late angiographic and clinical results similar to DEB but inferior to EES. (Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment [RIBS VI]; NCT02672878).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2017.06.064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of structural design on the mechanical performances of poly-L-lactic acid cardiovascular scaffolds using FEA and in vitro methods.
J Mech Behav Biomed Mater
December 2024
Department of Bionanosystem Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Department of Bionanotechnology and Bioconvergence Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Department of Mechanical Design Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Advanced Mechanical Components Design & Research Center, Jeonbuk National University, Jeonju 54896, Republic of Korea; Innovative Mechanobio Active Materials Based Medical Device Demonstration Center, Jeonbuk National University, Jeonju 54896, Republic of Korea. Electronic address:
Article Synopsis
- This study aimed to explore new scaffold geometries for improving the mechanical performance of Poly-L-lactic Acid (PLLA) bioresorbable vascular scaffolds (BVS) using finite element analysis (FEA) and lab experiments.
- Four different scaffold designs were subjected to simulations and tests, focusing on various mechanical properties like crush resistance and radial strength.
- The results revealed that Design B outperformed others in key performance metrics, suggesting new PLLA scaffold geometries could enhance their use in cardiovascular applications.
Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk.
JACC Cardiovasc Interv
November 2024
Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland; Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland; University of Bern, Bern, Switzerland. Electronic address:
Background: Abbreviated antiplatelet therapy (APT) reduces bleeding without increasing ischemic events in largely unselected high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI). Diabetes mellitus (DM) is associated with higher ischemic risk, and its impact on the safety and effectiveness of abbreviated APT in HBR PCI patients remains unknown.
Objectives: This study sought to investigate the comparative effectiveness of abbreviated (1 month) vs standard (≥3 months) APT in HBR patients with and without DM after biodegradable polymer sirolimus-eluting coronary stent implantation.
Magnesium-based bioresorbable flow diverter for intracranial aneurysms: a pilot study of biocompatibility and bioresorption in a rabbit vascular model.
J Neurointerv Surg
November 2024
Neurosurgery, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, Japan.
Article Synopsis
- The study investigates the effectiveness of two types of bioresorbable flow diverters made from a magnesium alloy: bare and PLLA-coated, comparing their bioresorption and biocompatibility in a rabbit vascular model.
- Both types of MgBRFDs were mechanically tested and implanted into rabbits; results showed that while both had good biocompatibility, the PLLA-coated version exhibited better preservation of structure and lower inflammation over time.
- The research concludes that the PLLA-coated MgBRFD is more clinically feasible for human use due to its slower bioresorption rate, allowing for improved performance during the healing process.
Employing synchrotron X-ray scattering and microscopy to explore microstructural mysteries in bioresorbable vascular scaffolds.
Acta Biomater
November 2024
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Crystal structure and morphology dictate the mechanical, thermal, and degradation properties of poly l-lactide (PLLA), the structural polymer of the first clinically approved bioresorbable vascular scaffolds (BVS). New experimental methods are developed to reveal the underlying mechanisms governing structure formation during the crimping step of the BVS manufacturing process. Our research specifically examines the "U-bends" - the region where the curvature is highest and stress is maximised during crimping, which can potentially lead to failure of the device with dramatic consequences on patient life.
View Article and Find Full Text PDFFive-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT.
Cardiovasc Revasc Med
November 2024
U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy. Electronic address:
Background: Data on Absorb bioresorbable vascular scaffold (BVS) use in patients presenting with ST-segment elevation myocardial infarction (STEMI) are limited. Furthermore, Absorb studies including STEMI patients lacked a prespecified implantation technique to optimize BVS deployment. This study examines the 5-year outcomes of BVS in STEMI patients using an optimized implantation strategy and the impact of prolonged dual antiplatelet therapy (DAPT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!